Association Between Bone Marrow Dosimetric Parameters and Acute Hematologic Toxicity in Anal Cancer Patients Treated With Concurrent Chemotherapy and Intensity-Modulated Radiotherapy

Loren K. Mell, David A. Schomas, Joseph K. Salama, Kiran Devisetty, Bulent Aydogan, Robert C. Miller, Ashesh B. Jani, Hedy L. Kindler, Arno J. Mundt, John C. Roeske, Steven J. Chmura

Research output: Contribution to journalArticle

135 Scopus citations

Abstract

Purpose: To test the hypothesis that the volume of pelvic bone marrow (PBM) receiving 10 and 20 Gy or more (PBM-V10 and PBM-V20) is associated with acute hematologic toxicity (HT) in anal cancer patients treated with concurrent chemoradiotherapy. Methods and Materials: We analyzed 48 consecutive anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiation therapy. The median radiation dose to gross tumor and regional lymph nodes was 50.4 and 45 Gy, respectively. Pelvic bone marrow was defined as the region extending from the iliac crests to the ischial tuberosities, including the os coxae, lumbosacral spine, and proximal femora. Endpoints included the white blood cell count (WBC), absolute neutrophil count (ANC), hemoglobin, and platelet count nadirs. Regression models with multiple independent predictors were used to test associations between dosimetric parameters and HT. Results: Twenty patients (42%) had Stage T3-4 disease; 15 patients (31%) were node positive. Overall, 27 (56%), 24 (50%), 4 (8%), and 13 (27%) experienced acute Grade 3-4 leukopenia, neutropenia, anemia, and thrombocytopenia, respectively. On multiple regression analysis, increased PBM-V5, V10, V15, and V20 were significantly associated with decreased WBC and ANC nadirs, as were female gender, decreased body mass index, and increased lumbosacral bone marrow V10, V15, and V20 (p < 0.05 for each association). Lymph node positivity was significantly associated with a decreased WBC nadir on multiple regression analysis (p < 0.05). Conclusion: This analysis supports the hypothesis that increased low-dose radiation to PBM is associated with acute HT during chemoradiotherapy for anal cancer. Techniques to limit bone marrow irradiation may reduce HT in anal cancer patients.

Original languageEnglish (US)
Pages (from-to)1431-1437
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Volume70
Issue number5
DOIs
StatePublished - Apr 1 2008

Keywords

  • Anal cancer
  • Bone marrow
  • Hematologic toxicity
  • IMRT
  • V

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'Association Between Bone Marrow Dosimetric Parameters and Acute Hematologic Toxicity in Anal Cancer Patients Treated With Concurrent Chemotherapy and Intensity-Modulated Radiotherapy'. Together they form a unique fingerprint.

  • Cite this

    Mell, L. K., Schomas, D. A., Salama, J. K., Devisetty, K., Aydogan, B., Miller, R. C., Jani, A. B., Kindler, H. L., Mundt, A. J., Roeske, J. C., & Chmura, S. J. (2008). Association Between Bone Marrow Dosimetric Parameters and Acute Hematologic Toxicity in Anal Cancer Patients Treated With Concurrent Chemotherapy and Intensity-Modulated Radiotherapy. International Journal of Radiation Oncology Biology Physics, 70(5), 1431-1437. https://doi.org/10.1016/j.ijrobp.2007.08.074